Polski  Wszystkie języki
Strona : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8
Lonza Group AG [CH0013841017]   
[12/09/2022]

Lonza Group AG : Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division

Lonza Group AG / Key words: Personnel Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division 12.09.2022 / 07:00 CET/CEST Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 Novemb... Więcej
 
Lonza Group AG [CH0013841017]   
[06/09/2022]

Lonza Group AG : Lonza and Touchlight collaborate on end-to-end mRNA offering

Lonza Group AG / Key words: Partnership Lonza and Touchlight collaborate on endtoend mRNA offering 06.09.2022 / 07:00 CET/CEST Collaboration expands Lonza’s endtoend offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA dbDNATM... Więcej
 
Lonza Group AG [CH0013841017]   
[22/07/2022]

Lonza Group AG : Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin

Lonza Group AG / Key words: Half Year Results Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin 22Jul2022 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to... Więcej
 
Lonza Group AG [CH0013841017]   
[01/07/2022]

Lonza Group AG : Maria Soler Nunez appointed as Head, Group Operations

Lonza Group AG / Key words: Personnel Maria Soler Nunez appointed as Head, Group Operations 01.07.2022 / 08:00   Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her... Więcej
 
Lonza Group AG [CH0013841017]   
[01/07/2022]

Lonza Group AG : Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)

Lonza Group AG / Key words: Expansion Lonza to Establish LargeScale, Commercial Drug Product Fill & Finish Facility in Stein CH 01Jul2022 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR... Więcej
 
Lonza Group AG [CH0013841017]   
[26/01/2022]

Lonza Group AG : Lonza Delivers Strong 2021 performance with 20% CER Sales Growth

Lonza Group AG / Key words: Annual Results Lonza Delivers Strong 2021 performance with 20% CER Sales Growth 26Jan2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad Hoc Release Pursuant to Art. 53 Listing Rules... Więcej
 
Lonza Group AG [CH0013841017]   
[12/10/2021]

Lonza Group AG : EQS-Adhoc: Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through Long-Term Growth

EQS GroupAdhoc: Lonza Group AG / Key words: Conference/Forecast Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through LongTerm Growth 12Oct2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.... Więcej
 
Strona : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8
Twoje ulubione spółki
Najczęściej czytane wiadomości od Lon...
{{KOLUMNA #1}}